CLS Therapeutics, LLC

CLS Therapeutics is a biopharmaceutical company developing next-generation gene therapies based on circulating nucleic acid science. Its lead candidate, CLS-014, is a first-in-class AAV-based therapy designed to eliminate harmful extracellular DNA in cancer patients, starting with pancreatic cancer. Founded by scientists and biotech entrepreneurs, the company aims to address unmet needs in oncology through innovative, cell-free DNA–targeted approaches.

George Tetz

Dr. George Tetz, MD, PhD is the CEO and co-founder of CLS Therapeutics, LLC, a New York–based biotech company developing gene therapies targeting circulating cell-free DNA. He leads the development of CLS‑014, an AAV-based DNase I therapy for pancreatic cancer. With over 18 years of experience in microbiology and drug discovery, Dr. Tetz has contributed to 18+ therapeutic programs, holds over 15 patents, and serves on advisory boards in his field.

Nil

Below is a list of company engagements where the filer has filed a Schedule 13D and/or engaged in a proxy campaign. As the filer does not file a Form 13F, current ownership information is not available.